戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 es resulting in treatment failure in several renal disorders.
2 ed in the pathogenesis of cardiovascular and renal disorders.
3 c response, confirming a key role for p53 in renal disorders.
4 are similar to those of a variety of chronic renal disorders.
5  of medical conditions, most notably bladder/renal disorders.
6 lomeruli (AG) have been described in several renal disorders.
7 thophysiological factors common to different renal disorders.
8 robiota might also drive the pathogenesis of renal disorders.
9 ession may contribute to a broad spectrum of renal disorders.
10 major cause of mortality in individuals with renal disorders.
11 strointestinal problems, hepatotoxicity, and renal disorders.
12 that underpin ciliary disease and associated renal disorders.
13 tics or as drug carriers in the treatment of renal disorders and present our views on the critical ch
14 brosis is the common outcome of many chronic renal disorders and, although the etiology varies (i.e.,
15 711 in the therapy of the cardiovascular and renal disorders associated with aging, diabetes, and hyp
16 nd that PARS inhibitors may be beneficial in renal disorders associated with oxidative stress-mediate
17 e (ADPKD) has long been considered a genetic renal disorder, but emerging evidence suggests that the
18                                          The renal disorder C3 glomerulopathy with dense deposit dise
19  respiratory disease, psychiatric disorders, renal disorders, cardiovascular disorders, and liver dis
20 oodpasture disease, an HLA-linked autoimmune renal disorder characterized by an immunodominant CD4(+)
21                  C3 glomerulopathy refers to renal disorders characterized by abnormal accumulation o
22            Cystic kidney diseases are common renal disorders characterized by the formation of fluid-
23 LDN19 function result in the inherited human renal disorder familial hypomagnesemia with hypercalciur
24 egmental glomerulosclerosis (FSGS), a common renal disorder in humans, and produce an apparent increa
25  conventional MGUS and assessed incidence of renal disorders in patients with light-chain MGUS.
26 e frequently called on to diagnose and treat renal disorders in pregnant women.
27 li seems to play a major role in a number of renal disorders, including glomerular diseases, ascribed
28 s a treatment not only for HIBM but also for renal disorders involving proteinuria and hematuria due
29 romoter of CKD (regardless of the underlying renal disorder leading to CKD), the extracellular-regula
30 and 2.33), hydramnios (RRs = 2.04 and 1.66), renal disorders (RRs = 1.54 and 2.56), and intrapartum f
31  the cellular and molecular basis for cystic renal disorders should lead to specific intervention in
32 rodegenerative diseases, metabolic syndrome, renal disorders, skin disorders, and cancer.
33 ve been linked to the pathogenesis of cystic renal disorders such as autosomal dominant polycystic ki
34       SSSS in adults is also associated with renal disorders, suggesting that levels of toxin in seru
35 ycystic kidney disease is a common inherited renal disorder that results from mutations in either PKD
36 grade 3 disorders included hepatobiliary and renal disorders (three [13%] at 200 mg twice a day), ast
37 l conditions ranging from cardiovascular and renal disorders to fibrotic diseases.
38 merging as a viable therapeutic strategy for renal disorders with predominantly complement-driven eti